Hyperthyroidism: Advantages and disadvantages of medical therapy

Surgical Clinics of North America

Volumn 84, Issue 3, 2004, Pages 833-847

  Pearce, Elizabeth N ^a,b   Braverman, Lewis E ^a,b  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMIODARONE; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; COLESTYRAMINE; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 2; IOPANOIC ACID; LIOTHYRONINE; LITHIUM; LUGOL; NEUTROPHIL CYTOPLASMIC ANTIBODY; POTASSIUM PERCHLORATE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THIONAMIDE DERIVATIVE; THYROXINE;

ACUTE HEPATITIS; AGRANULOCYTOSIS; ARTHRALGIA; BLEEDING; CHOANA ATRESIA; CHOLESTASIS; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; ENDOCRINE OPHTHALMOPATHY; ESOPHAGUS ATRESIA; FEVER; GRAVES DISEASE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; HYPOCALCEMIA; HYPOPARATHYROIDISM; LIVER FAILURE; LIVER TOXICITY; NECK PAIN; OSTEOPOROSIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RASH; RECURRENT LARYNGEAL NERVE PALSY; REVIEW; SIDE EFFECT; SKIN APLASIA; THYROID CRISIS; THYROIDECTOMY; THYROIDITIS; THYROTOXICOSIS; TOXIC GOITER; URTICARIA;

ANTITHYROID AGENTS; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; PATIENT SELECTION; THYROIDECTOMY;

EID: 2442418075     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2004.01.007     Document Type: Review

References (99)

1. Ross DS. Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol Metab Clin North Am 1998;27(1):169-85.
2. Cooper DS. Hyperthyroidism. Lancet 2003;362(9382):459-68.
3. Streetman DD, Khanderia U. Diagnosis and treatment of Graves disease. Ann Pharmacother 2003;37(7-8):1100-9.
4. Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine (Baltimore) 1994;73(1):1-7.
5. Vanhoenacker FM, Pelckmans MC, De Beuckeleer LH, Colpaert CG, De Schepper AM. Thyroid acropachy: correlation of imaging and pathology. Eur Radiol 2001;11(6):1058-62.
6. Belfiore A, Sava L, Runello F, Tomaselli L, Vigneri R. Solitary autonomously functioning thyroid nodules and iodine deficiency. J Clin Endocrinol Metab 1983;56(2):283-7.
7. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 1991;229(5):415-20.
8. Berghout A, Wiersinga WM, Smits NJ, Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med 1990;89(5):602-8.
9. Elte JW, Bussemaker JK, Haak A. The natural history of euthyroid multinodular goitre. Postgrad Med J 1990;66(773):186-90.
10. Hamburger JI. Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab 1980;50(6):1089-93.
11. Livadas DP, Koutras DA, Souvatzoglou A, Beckers C. The toxic effect of small iodine supplements in patients with autonomous thyroid nodules. Clin Endocrinol (Oxf) 1977;7(2):121-7.
12. Ermans AM, Camus M. Modifications of thyroid function induced by chronic administration of iodide in the presence of "autonomous" thyroid tissue. Acta Endocrinol (Copenh) 1972;70(3):463-75.
13. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001;22(2):240-54.
14. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997;126(1):63-73.
15. Eaton SE, Euinton HA, Newman CM, Weetman AP, Bennet WM. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 2002;56(1):33-8.
16. Weetman AP, McGregor AM, Hall R. Evidence for an effect of antithyroid drugs on the natural history of Graves' disease. Clin Endocrinol (Oxf) 1984;21(2):163-72.
17. Leonard JL, Rosenberg IN. Thyroxine 5′-deiodinase activity of rat kidney: observations on activation by thiols and inhibition by propylthiouracil. Endocrinology 1978;103(6):2137-44.
18. Cooper DS. Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD, editors. Werner & Ingbar's the thyroid. 8th edition. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 691-715.
19. Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol (Oxf) 2001;54(3):385-90.
20. Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 1995;88(9):973-6.
21. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994;330(24):1731-8.
22. Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Scottish Automated Follow-Up Register Group. Clin Endocrinol (Oxf) 1989;31(2):209-18.
23. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the e.cacy of treatment duration. J Clin Endocrinol Metab 1990;70(3):675-9.
24. Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, et al. Response to methimazole in Graves' disease. The European Multicenter Study Group. Clin Endocrinol (Oxf) 1995;43(3):257-63.
25. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000;85(3):1038-42.
26. Glinoer D, de Nayer P, Bex M. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001;144(5):475-83.
27. Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, et al. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf) 1998;49(4):451-7.
28. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996;334(4):220-4.
29. Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S, et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. J Clin Endocrinol Metab 1998;83(3):814-8.
30. Raber W, Kmen E, Waldhausl W, Vierhapper H. Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. Eur J Endocrinol 2000;142(2):117-24.
31. Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves' disease. Endocrinol Metab Clin North Am 1998;27(1):225-47.
32. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983;98(1):26-9.
33. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 1993;118(6):424-8.
34. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82(6):1727-33.
35. Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. Am J Gastroenterol 2001;96(1):165-9.
36. Testa G, Trevino J, Bogetti D, Layden T, Wiley T, Sankary H, et al. Liver transplantation for propylthiouracil-induced acute hepatic failure. Dig Dis Sci 2003;48(1):190-1.
37. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003;37(2):224-8.
38. Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract 2002;8(3):222-4.
39. Sera N, Ashizawa K, Ando T, Abe Y, Ide A, Usa T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000;10(7):595-9.
40. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85(11):4270-3.
41. Dolman KM, Gans RO, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993;342(8872):651-2.
42. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McEldu. A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving antithyroid medication. Eur J Endocrinol 2000;142(6):587.
43. Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPOANCA and clinical manifestations. Clin Endocrinol (Oxf) 2001;54(5):651-4.
44. Dhillon SS, Singh D, Doe N, Qadri AM, Ricciardi S, Schwarz MI. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 1999;116(5):1485-8.
45. Erten Y, Bodur H, Sahiner S, Tolunay O, Akkaya V, Canbakan B, et al. Antineutrophil cytoplasmic antibody associated vasculitis and rapidly progressive glomerulonephritis as a complication of propylthiouracil therapy. Clin Endocrinol (Oxf) 2002;57(5):699-700.
46. Helfgott SM, Smith RN. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2002. A 21-year-old man with arthritis during treatment for hyperthyroidism. N Engl J Med 2002;347(2):122-30.
47. Wada N, Mukai M, Kohno M, Notoya A, Ito T, Yoshioka N. Prevalence of serum antimyeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. Endocr J 2002;49(3):329-34.
48. Kawachi Y, Nukaga H, Hoshino M, Iwata M, Otsuka F. ANCA-associated vasculitis and lupus-like syndrome caused by methimazole. Clin Exp Dermatol 1995;20(4):345-7.
49. Hori Y, Arizono K, Hara S, Kawai R, Hara M, Yamada A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamazole therapy. Nephron 1996;74(4):734-5.
50. Tsai MH, Chang YL, Wu VC, Chang CC, Huang TS. Methimazole-induced pulmonary hemorrhage associated with antimyeloperoxidase-antineutrophil cytoplasmic antibody: a case report. J Formos Med Assoc 2001;100(11):772-5.
51. D'Cruz D, Chesser AM, Lightowler C, Comer M, Hurst MJ, Baker LR, et al. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with antithyroid drug treatment. Br J Rheumatol 1995;34(11):1090-1.
52. Masiukiewicz US, Burrow GN. Hyperthyroidism in pregnancy: diagnosis and treatment. Thyroid 1999;9(7):647-52.
53. Mortimer RH, Cannell GR, Addison RS, Johnson LP, Roberts MS, Bernus I. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 1997;82(9):3099-102.
54. Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab 1997;82(11):3633-6.
55. Diav-Citrin O, Ornoy A. Teratogen update: antithyroid drugs-methimazole, carbimazole, and propylthiouracil. Teratology 2002;65(1):38-44.
56. Karlsson FA, Axelsson O, Melhus H. Severe embryopathy and exposure to methimazole in early pregnancy. J Clin Endocrinol Metab 2002;87(2):947-9.
57. Di Gianantonio E, Schaefer C, Mastroiacovo PP, Cournot MP, Benedicenti F, Reuvers M, et al. Adverse effects of prenatal methimazole exposure. Teratology 2001;64(5):262-6.
58. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 2001;86(6):2354-9.
59. Kampmann JP, Johansen K, Hansen JM, Helweg J. Propylthiouracil in human milk. Revision of a dogma. Lancet 1980;1(8171):736-7.
60. Low LC, Lang J, Alexander WD. Excretion of carbimazole and propylthiouracil in breast milk. Lancet 1979;2(8150):1011.
61. Johansen K, Andersen AN, Kampmann JP, Molholm Hansen JM, Mortensen HB. Excretion of methimazole in human milk. Eur J Clin Pharmacol 1982;23(4):339-41.
62. Momotani N, Yamashita R, Makino F, Noh JY, Ishikawa N, Ito K. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol (Oxf) 2000;53(2):177-81.
63. Azizi F, Khoshniat M, Bahrainian M, Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J Clin Endocrinol Metab 2000;85(9):3233-8.
64. Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992;93(1):61-8.
65. Wartofsky L. Thyrotoxic storm. In: Braverman LE, Utiger RD, editors. Werner and Ingbar's the thyroid. 8th edition. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 679-84.
66. Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1993;38(1):39-43.
67. Martino E, Aghini-Lombardi F, Mariotti S, Lenziardi M, Baschieri L, Braverman LE, et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 1986;9(3):201-7.
68. Stewart RD, Murray IP. Effect of small doses of carrier iodide upon the organic binding of radioactive iodine by the human thyroid gland. J Clin Endocrinol Metab 1967;27(4):500-8.
69. Chang DC, Wheeler MH,Woodcock JP, Curley I, Lazarus JR, Fung H, et al. The effect of preoperative Lugol's iodine on thyroid blood flow in patients with Graves' hyperthyroidism. Surgery 1987;102(6):1055-61.
70. Braga M, Cooper DS. Clinical review 129: oral cholecystographic agents and the thyroid. J Clin Endocrinol Metab 2001;86(5):1853-60.
71. Fontanilla JC, Schneider AB, Sarne DH. The use of oral radiographic contrast agents in the management of hyperthyroidism. Thyroid 2001;11(6):561-7.
72. Martino E, Balzano S, Bartalena L, Loviselli A, Sica V, Petrini L, et al. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. J Endocrinol Invest 1991;14(10):847-51.
73. 131I therapy for hyperthyroidism. Acta Radiol Oncol 1981;20(3):161-6.
74. Nygaard B, Hegedus L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 1999;159(12):1364-8.
75. Cunnien AJ, Hay ID, Gorman CA, O.ord KP, Scanlon PW. Radioiodine-induced hypothyroidism in Graves' disease: factors associated. J Nucl Med 1982;23(11):978-83.
76. Shafer RB, Nuttall FQ. Acute changes in thyroid function in patients treated with radioactive iodine. Lancet 1975;2(7936):635-7.
77. McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD. Radioiodine-induced thyroid storm. Case report and literature review. Am J Med 1983;75(2):353-9.
78. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the e.cacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001;86(8):3488-93.
79. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic e.cacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998;83(2):685-7.
80. Bonnema SJ, Bartalena L, Toft AD, Hegedus L. Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goiters. Eur J Endocrinol 2002;147(1):1-11.
81. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998;129(8):632-5.
82. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326(26):1733-8.
83. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338(2):73-8.
84. Palit TK, Miller CC 3rd, Miltenburg DM. The effcacy of thyroidectomy for Graves' disease: a meta-analysis. J Surg Res 2000;90(2):161-5.
85. Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, et al. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a casecontrol study. Clin Endocrinol (Oxf) 1999;51(4):503-8.
86. Alsanea O, Clark OH. Treatment of Graves' disease: the advantages of surgery. Endocrinol Metab Clin North Am 2000;29(2):321-37.
87. Bogazzi F, Miccoli P, Berti P, Cosci C, Brogioni S, Aghini-Lombardi F, et al. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. Surgery 2002;132(6):1114-7 [discussion: 1118].
88. Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf) 1991;35(5):439-42.
89. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1(2):129-35.
90. Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999;84(10):3636-41.
91. Farwell AP, Abend SL, Huang SK, Patwardhan NA, Braverman LE. Thyroidectomy for amiodarone-induced thyrotoxicosis. JAMA 1990;263(11):1526-8.
92. Bogazzi F, Bartalena L, Cosci C, Brogioni S, Dell'Unto E, Grasso L, et al. Treatment of Type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab 2003;88(5):1999-2002.
93. Koutras DA. Subclinical hyperthyroidism. Thyroid 1999;9(3):311-5.
94. Ross DS. Subclinical thyrotoxicosis. In: Braverman L, Utiger R, editors. Werner & Ingbar's the thyroid. 8th edition. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 1007-12.
95. Surks MI, Ocampo E. Subclinical thyroid disease. Am J Med 1996;100(2):217-23.
96. Utiger RD. Subclinical hyperthyroidism - just a low serum thyrotropin concentration, or something more? N Engl J Med 1994;331(19):1302-3.
97. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 1998;48(3):285-90.
98. Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during antithyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 1994;41(4):421-4.
99. Sgarbi JA, Villaca FG, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003;88(4):1672-7.